

Publication List: Fredrik Schjesvold, Department of Haematology, Oslo University Hospital, Oslo, Norway.

1: Wang D, Fløisand Y, Myklebust CV, Bürgler S, Parente-Ribes A, Hofgaard PO, Bogen B, Taskén K, Tjønnfjord GE, Schjesvold F, Dalgaard J, Tveita A, Munthe LA. Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice. *Leukemia*. 2017 Mar 28. doi: 10.1038/leu.2017.69. [Epub ahead of print] PubMed PMID: 28232741.

2: Schjesvold FH. Immunologiske mekanismer for drap av kreftceller. *Tidsskr Nor Laegeforen*. 2017 Jan 10;137(1):58. doi: 10.4045/tidsskr.16.0963. eCollection 2017 Jan 10. Norwegian. PubMed PMID: 28073239.

3: Torfoss D, Fladhagen T, Holte H, Brinch L, Schjesvold FH, Fløisand Y, Nyquist E, Dalgaard J, Meyer P, Lehmann AK, Hammerstrøm J, Skjelbakken T, Høiby EA, Sandvik L, Kvaløy S. Benzylpenicillin plus an aminoglycoside versus meropenem in neutropenic lymphoma and leukaemia patients with a suspected bacterial infection: a randomized, controlled trial. *Clin Microbiol Infect*. 2017 Mar;23(3):179-187. doi: 10.1016/j.cmi.2016.10.019. Epub 2016 Oct 26. PubMed PMID: 27793737.

4: Tveita AA, Schjesvold F, Haabeth OA, Fauskanger M, Bogen B. Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens. *Cancer Res*. 2015 Aug 15;75(16):3268-78. doi: 10.1158/0008-5472.CAN-14-3640. Epub 2015 Jun 2. PubMed PMID: 26038231.

5: Ghanima W, Khelif A, Waage A, Michel M, Tjønnfjord GE, Romdhan NB, Kahrs J,

Darne B, Holme PA; RITP study group.. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet*. 2015 Apr 25;385(9978):1653-61. doi: 10.1016/S0140-6736(14)61495-1. Epub 2015 Feb 5. PubMed PMID: 25662413.

6: Tveita AA, Schjesvold FH, Sundnes O, Haabeth OA, Haraldsen G, Bogen B. Indirect CD4+ T-cell-mediated elimination of MHC II(NEG) tumor cells is spatially restricted and fails to prevent escape of antigen-negative cells. *Eur J Immunol*. 2014 Sep;44(9):2625-37. doi: 10.1002/eji.201444659. Epub 2014 Jun 20. PubMed PMID: 24846412.

7: Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, Omholt H, Munthe LA, Dembic Z, Corthay A, Bogen B. How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules? *Front Immunol*. 2014 Apr 15;5:174. doi: 10.3389/fimmu.2014.00174. eCollection 2014 Apr 15. Review. PubMed PMID: 24782871; PubMed Central PMCID: PMC3995058.

8: Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI; AMPLIFY Investigators.. Oral apixaban for the treatment of acute venous thromboembolism. *N Engl J Med*. 2013 Aug 29;369(9):799-808. doi: 10.1056/NEJMoa1302507. Epub 2013 Jul 1. PubMed PMID: 23808982.

9: Schjesvold F, Wiencke K, Tjønnfjord GE. [Investigation of anemia]. *Tidsskr Nor Lægeforen*. 2013 Mar 19;133(6):610. doi: 10.4045/tidsskr.13.0256. Norwegian. PubMed PMID: 23552139.

10: Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN Investigators.. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. *N Engl J Med*. 2013 Feb 7;368(6):513-23. doi: 10.1056/NEJMoa1111096. PubMed PMID: 23388003.

11: Schjesvold FH. [Investigation of amyloidosis]. *Tidsskr Nor Laegeforen*. 2013 Feb 5;133(3):266. doi: 10.4045/tidsskr.13.0044. Norwegian. PubMed PMID: 23381155.

12: Tazmini K, Bakken HN, Schjesvold FH. A woman in her seventies with reduced general condition, dyspnoea and generalised pain. *Tidsskr Nor Laegeforen*. 2012 Sep 18;132(17):1969-72. English, Norwegian. Erratum in: *Tidsskr Nor Laegeforen*. 2012 Oct 30;132(20):2260. PubMed PMID: 23007363.

13: Hjorth M, Hjertner Ø, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andréasson B, Billström R, Carlson K, Carlsson MS, Flogegård M, Forsberg K, Gimsing P, Karlsson T, Linder O, Nahi H, Othzén A, Swedin A; Nordic Myeloma Study Group (NMSG).. Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study. *Eur J Haematol*. 2012 Jun;88(6):485-96. doi: 10.1111/j.1600-0609.2012.01775.x. Epub 2012 Mar 30. PubMed PMID: 22404182; PubMed Central PMCID: PMC3492844.

14: Schjesvold FH. [Erythrocytosis as a problem]. *Tidsskr Nor Laegeforen*. 2009 Nov 19;129(22):2387; author reply 2387. doi: 10.4045/tidsskr.09.1196. Norwegian. PubMed PMID: 19935946.

15: Schjesvold FH, Sjo M, Tangen JM, Hammerstrøm J, Brinch L. [High-dose treatment of systemic AL-amyloidosis with autologous stem cell support]. Tidsskr Nor Laegeforen. 2008 Jun 12;128(12):1392-6. Norwegian. PubMed PMID: 18552900.